FDA has approved bupivacaine hydrochloride injection, USP (Sagent and Strides Arcolab), a local or regional anesthetic, for use in surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and obstetrical procedures.
FDA has approved bupivacaine hydrochloride injection, USP (Sagent and Strides Arcolab), a local or regional anesthetic, for use in surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and obstetrical procedures.
Bupivacaine will be available in 6 single-dose and 2 multidose latex-free vials. According to IMS data, the 2011 US market for injectable bupivacaine approximates $29 million. As with all products in Sagent's portfolio, bupivacaine features the company's PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors.
Bupivacaine is the 13th product approved under the joint venture between Sagent and Strides Arcolab. Under the collaboration, Strides is responsible for developing and supplying injectable products that Sagent will market in the United States.
Detailed information about the indications, warnings, complete side-effect profile, and full prescribing information will be available in the package insert. Visit www.SagentPharma.com for more information.
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More